Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M74,180Revenue (TTM) $M23,002Net Margin (%)15.7Altman Z-Score1.6
Enterprise Value $M78,484EPS (TTM) $1.4Operating Margin %21.9Piotroski F-Score6
P/E(ttm)21.1Beneish M-Score-2.3Pre-tax Margin (%)16.0Higher ROA y-yY
Price/Book4.810-y EBITDA Growth Rate %-2.9Quick Ratio0.7Cash flow > EarningsY
Price/Sales3.35-y EBITDA Growth Rate %-8.6Current Ratio0.9Lower Leverage y-yY
Price/Free Cash Flow39.4y-y EBITDA Growth Rate %23.6ROA % (ttm)5.7Higher Current Ratio y-yN
Dividend Yield %4.8PEG--ROE % (ttm)24.2Less Shares Outstanding y-yN
Payout Ratio %144Shares Outstanding M2,530ROIC % (ttm)17.7Gross Margin Increase y-yY

Gurus Latest Trades with AZN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

AZN is held by these investors:

AZN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ASTRAZENECA PLC10% Owner 2014-11-12Sell2,000,000$1773.59view

Quarterly/Annual Reports about AZN:

    News about AZN:

    Articles On GuruFocus.com
    Dodge & Cox Comments on AstraZeneca Feb 06 2017 
    Dodge & Cox's Stock Fund 4th Quarter Commentary Jan 16 2017 
    Big Alzheimer Flop Creates Buying Opportunity for Eli Lilly Dec 10 2016 
    8 Uncommon Stocks NWQ Managers Is Buying Dec 06 2016 
    How Could a Potential Nexium Lawsuit Affect AstraZeneca? Nov 03 2016 
    Novo Nordisk Is Being Ignored Oct 06 2016 
    Novartis Is Surviving Oct 03 2016 
    10 Stocks Dodge & Cox Keep Buying Sep 22 2016 
    Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
    Francis Chou Raises Stake in Resolute Forest Products Mar 20 2016 

    More From Other Websites
    Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs Feb 24 2017
    Keytruda: Merck & Co.’s Immuno-Oncology Blockbuster Drug Feb 22 2017
    Merck & Co.’s Segment-Wise Revenues for 4Q16 Feb 22 2017
    Analyst: Buy AstraZeneca On The Turnaround Story Feb 22 2017
    $250M deal: AstraZeneca sells rights to cancer therapy Feb 21 2017
    The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan,... Feb 21 2017
    Sanofi’s Unique Foothold in Diabetes and Cardiovascular Feb 20 2017
    AstraZeneca Could Give Pfizer, Tesaro Leg Up In Breast Cancer: Leerink Feb 17 2017
    Clovis, Tesaro Soar on Astrazeneca Phase Three News Feb 17 2017
    FTSE gains for third week as Unilever rises, Coca Cola HBC sets record Feb 17 2017
    European Benchmarks Fall, But London Bucks Trend on Takeover Activity Feb 17 2017
    [$$] AstraZeneca boosted by positive breast cancer trial Feb 17 2017
    AstraZeneca's Lynparza meets main goal in breast cancer study Feb 17 2017
    AstraZeneca Stock Rises On Successful Breast Cancer Drug Trial Feb 17 2017
    Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ Feb 17 2017
    LYNPARZA™ (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast... Feb 17 2017
    Britain's FTSE set for week of modest gains, pharmas lead Feb 17 2017
    Top AstraZeneca shareholder Woodford adds to stake, bullish on outlook Feb 17 2017
    Top AstraZeneca shareholder Woodford adds to stake, bullish on outlook Feb 16 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)